Are there specific biomarkers that can predict the success of ribociclib and letrozole rechallenge in breast cancer patients?
Abstract
Biomarkers such as ctDNA, NLR, TK1 activity, and intrinsic subtypes show potential in predicting outcomes for breast cancer patients treated with ribociclib and letrozole, but further validation is needed.
Fields of Study & Subjects
Advanced Breast Cancer Therapies
Breast Cancer Treatment Studies
PARP inhibition in cancer therapy
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 24 February 2026
- Language
- EN